ERFSF (Eurofins Scientific SE) NonCurrent Deferred Revenue: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ERFSF Eurofins Scientific SE ERFSF
80 GF Score
Price $82.96
GF Value $75.64
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Eurofins Scientific SE NonCurrent Deferred Revenue?

Eurofins Scientific SE ERFSF +2.18% 80 NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus rates ERFSF with a GF Score™ of 80/100 and a GF Value™ of $75.64 (Fairly Valued). The stock has 6 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Eurofins Scientific SE's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0 Mil.

Eurofins Scientific SE NonCurrent Deferred Revenue Related Terms

Eurofins Scientific SE NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Eurofins Scientific SE's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eurofins Scientific SE NonCurrent Deferred Revenue Chart

Eurofins Scientific SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eurofins Scientific SE Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ERFSF
80GF Score
Eurofins Scientific SE ERFSF
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0 Mil mean?
Eurofins Scientific SE (ERFSF) has a NonCurrent Deferred Revenue of $0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Eurofins Scientific SE and its competitors.
Is Eurofins Scientific SE's NonCurrent Deferred Revenue too high?
Eurofins Scientific SE's current NonCurrent Deferred Revenue is $0 Mil. Overall, Eurofins Scientific SE has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's NonCurrent Deferred Revenue compare to TMO and DHR?
Eurofins Scientific SE's NonCurrent Deferred Revenue of $0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Eurofins Scientific SE and its competitors. Eurofins Scientific SE's current NonCurrent Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.64, compared to a current price of $82.96 — trading 9.7% above its estimated fair value. The current NonCurrent Deferred Revenue is $0 Mil. Eurofins Scientific SE's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?

Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued. The current stock price of $82.96 is trading 9.7% above its estimated GF Value™ of $75.64. GuruFocus considers Eurofins Scientific SE to be Fairly Valued.

Key valuation signals for ERFSF:

  • NonCurrent Deferred Revenue: $0 Mil
  • GF Value™: $75.64 vs. price of $82.96 (9.7% above fair value)
  • GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eurofins Scientific SE Business Description

Address 23 Val Fleuri, Luxembourg, LUX, 1526
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
80GF Score

Get the complete analysis for ERFSF

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.96
Price
$75.64
GF Value